Abstract
We tested the hypothesis that selegiline can attenuate dopamine depletion if administered following high doses of methamphetamine that cause neurotoxicity in the striatum. Methamphetamine produced decreases of 50% or greater in both striatal concentrations of dopamine and combined concentrations of homovanillic acid and DOPAC in mice. For animals not exposed to methamphetamine, chronic treatment with selegiline over 18 days caused biphasic effects on striatal dopamine content, with decreases, no effect, or increases observed for mice receiving treatment with 0.02, 0.2, and 2.0 mg/kg, respectively. Selegiline failed to modify methamphetamine-induced reductions in striatal dopamine content or combined concentrations of homovanillic acid and DOPAC. Significant increases in mortality following the onset of selegiline treatment (24 hours after the initial dose of methamphetamine) occurred in methamphetamine-treated mice that received saline or 2.0 mg/kg of selegiline, but not for mice treated with 0.02 or 0.2 mg/kg of selegiline. These results indicate that selegiline fails to attenuate dopamine depletion when administered chronically following exposure to methamphetamine, but may attenuate methamphetamine-induced mortality. In control animals that did not receive methamphetamine, low doses of selegiline produced decreases the concentration of striatal dopamine, while high dose treatment caused increases in striatal dopamine content.
Similar content being viewed by others
REFERENCES
Derlet, R. W. and Heischober, B. 1990. Methamphetamine. Stimulant of the 1990s?. [Review] [46 refs]. West. J. Med. 153:625–628.
Seiden, L. S. and Sabol, K. E. 1994. Neurotoxicity of methamphetamine-related drugs and cocaine. Pages 825–843, in Chang, L. W. and Dyer, R. S. (eds.), Handbook of Neurotoxicology Marcel Dekker, Inc., New York.
Cadet, J. L. and Brannock, C. 1998. Free radicals and the pathobiology of brain dopamine systems. [Review] [131 refs]. Neurochem. Int. 32:117–131.
Woolverton, W. L., Ricaurte, G. A., Forno, L. S., and Seiden, L. S. 1989. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res. 486:73–78.
Villemangen, V., Yuan, J., Wong, D. F., Dannals, R. F., Hatzidimitriou, G., Mathews, W. B., Ravert, H. T., McCann, U. D., and Ricaurte, G. A. 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence fro [11C]WIN-35,428 positron emission tomagraphy studies and direct in vitro determinations. J. Neurochem. 18:419–427.
Wilson, J. M., Kalasinsky, K. S., Levey, A. I., et al. 1996. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nature Med. 2:699–703.
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., and Ricaurte, G. A. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J. Neuroscience 18:8417–8422.
Wallace, T. L., Gudelsky, G. A., and Vorhees, C. V. 1999. Methamphetamine-induced neurotoxicity alters locomotor activity, stereotypic behavior, and stimulated dopamine release in the rat. J. Neuroscience 19:9141–9148.
Friedman, S. D., Castaneda, E., and Hodge, G. K. 1998. Long-term monoamine depletion, differential recovery, and subtle behavioral impairment following methamphetamine-induced neurotoxicity. Pharmacology, Bioch. & Behav. 61:35–44.
Melega, W. P., Raleigh, M. J., Stout, D. B., Lacan, G., Huang, S. C., and Phelps, M. E. 1997. Recovery of striatal dopamine function after acute amphetamine-and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 766:113–120.
Melega, W. P., Raleigh, M. J., Stout, D. B., Huang, S. C., and Phelps, M. E. 1997. Ethological and 6-[18F]fluoro-L-DOPAPET profiles of long-term vulnerability to chronic amphetamine. Behav. Brain Res. 84:259–268.
Cass, W. A. and Manning, M. W. 1999. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine. J. Neuroscience 19:7653–7660.
Bowyer, J. F., Frame, L. T., Clausing, P., Nagamoto-Combs, K., Osterhout, C. A., Sterling, C. R., and Tank, A. W., 1998. Longterm effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J. Pharmacol. & Exper. Therap. 286:1074–1085.
Heinonen, E. H. and Lammintausta, R. 1991. A review of the pharmacology of selegiline. Acta Neurol. Scand. 84:44–59.
Knoll, J. 1996. (-)Deprenyl (selegiline) in Parkinson's disease: a pharmacologist's comment. Biomed. Pharmacotherap. 50:315–317.
Knoll, J. and Miklya, I. 1994. Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch. Int. Pharmacodynam. Therap. 328:1–15.
Lamensdorf, I., Youdim, M. B., and Finberg, J. P. 1996. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 67:1532–1539.
Wagner, G. C. and Walsh, S. L. 1991. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage. Int. J. Develop. Neurosci. 9:171–174.
Johnson, S. K., Medina, D., and Wagner, G. C. 1992. The effects of deprenyl on methamphetamine-induced dopamine depletions. J. Neural Trans.—Gen. Sec. 89:123–127.
Tatton, W. G. and Greenwood, C. E. 1991. Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J. Neurosci. Res. 30:666–672.
Hao, R., Ebadi, M., and Pfeiffer, R. F. 1995. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease. Neurosci. Lett. 200:77–80.
Paterson, I. A., Barber, A. J., Gelowitz, D. L., and Voll, C. 1997. (-)Deprenyl reduces delayed neuronal death of hippocampal pyramidal cells. Neurosci. Biobehav. Rev. 21:181–186.
Lahtinen, H., Koistinaho, J., Kauppinen, R., Haapalinna, A., Keinanen, R., and Sivenius, J. 1997. Selegiline treatment after transient global ischemia in gerbils enhances the survival of CA1 pyramidal cells in the hippocampus. Brain Res. 757:260–267.
Ansari, K. S., Yu, P. M., Kruck, T. P., and Tatton, W. G. 1993. Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition. J. Neuroscience 13:4042–4053.
Grasing, K. and Ghosh, S. 1998. Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abinence following opiate withdrawal. Neuropharmacology 37:1007–1017.
Kreek, M. J. 1997. Opiates and cocaine addictions: challenge for pharmacotherapies. Pharmacol. Biochem. Behav. 57:551–569.
Dackis, C. A. and Gold, M. S. 1985. New concepts in cocaine addiction: the dopamine depletion hypothesis. Neurosci. Biobehav. Rev. 9:469–477.
De Vito, M. J. and Wagner, G. C. 1989. Methamphetamineinduced neuronal damage: A possible role for free radicals. Neuropharmacology 28:1145–1150.
Cass, W. A. 1996. GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine. J. Neuroscience 16:8132–8139.
Ohmori, T., Abekawa, T., and Koyama, T. 1996. The role of glutamate in behavioral and neurotoxic effects of methamphetamine. Neurochem. Int. 29:301–307.
Cunfeng, P. and Vorhees, C. V. 1995. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: an immunocytochemical study. Synapse 19:97–104.
Bowyer, J. F., Davies, D. L., Schmued, L., Broening, H. W., Newport, G. D., Slikker, W., and Holson. R. R. 1994. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J. Pharmacol. Exper. Ther. 268:1571–1580.
Itzhak, Y., Gandia, C., Huang, P. L., and Ali, S. F. 1998. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity. J. Pharmacol. & Exp. Therapeut. 284:1040–1047.
Itzhak, Y. and Ali, S. F. 1996. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamineinduced neurotoxicity in vivo. J. Neurochem. 67:1770–1773.
Tomac, A., Lindqvist, E., Lin, L. H., Ogren, S. O., Young, D., Hoffer, B. J., and Olson, L. 1995. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335–339.
Bowyer, J. F., Tank. A. W., Newport, G. D., Slikker, W. J., Ali, S. F., and Holson, R. R. 1992. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J. Pharmacol. & Exper. Therapeut. 260:817–824.
Miller, D. B. and O'Callaghan, J. P. 1994. Environment-, drug,-and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J. Pharmacol. Exper. Ther. 270:752–760.
Ricaurte, G. A., Guillery. R. W., Seiden, L. S., Schuster, C. R., and Moore, R. Y. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res. 235:93–103.
Caine, S. B. and Koob, G. F. 2000. Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat. Behav. Pharm. 6:333–347.
Wiener, H. L., Hashim, A., Lajtha, A., and Sershen, H. 1989. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice. J. Neurosci. Res. 23:326–329.
Waldmeier, P. C. and Felner, A. E. 1978. Deprenil, loss of selectivity for inhibition of b-type MAO after repeated treatment. Biochem. Pharmacol. 27:801–806.
Gelowitz, D. L., Richardson, J. S., Wishart, T. B., Yu, P. H., and Lai, C. T. 1994. Chronic L-deprenyl or L-amphetamine: Equal cognitive enhancement, unequal MAO inhibition. Pharmacol. Biochem. Behav. 47:41–45.
Ekstedt, B., Magyar, K., and Knoll, J. 1979. Does the B form selective monoamine oxidase inhibitor lose selectivity by longterm treatment? Biochem. Pharm. 28:919–923.
Tipton, K. F. and Singer, T. P. 1993. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. [Review] [155 refs]. J. Neurochem. 61: 1191–1206.
Trulson, M. E., Cannon, M. S., Faegg, T. S., and Raese, J. D. 1985. Effects of chronic methamphetamine on the nigral-striatal dopamine system in rat brain: tyrosine hydroxylase immunochemistry and quantitative light microscopic studies. Brain Res. Bull. 15:569–577.
Tatton, W. G. and Chalmers-Redman, R. M. 1996. Modulation of gene expression rather than monamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 47:S171–S183.
Gerlach, M., Youdim, M. B. H., and Riederer, P. 1996. Pharmacology of selegiline. Am. Acad. Neurol. 47: S137–S143.
Thiffault, C., Lamarra-Theroux, L., Quirion, R., and Poirier, J. 1997. L-deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Brain Res. 44:238–244.
Yu, P. H., Davis, B. A., Fang, J., and Boulton, A. A. 1994. Neuroprotective effects of some monoamine oxidase-B inhibitors against DSP-4-induced noradrenaline depletion in the mouse hippocampus. J. Neurochem. 63:1820–1828.
Finnegan, K. T., Skratt, J. J., Irwin, I., DeLanney, L. E., and Langston, J. W. 1990. Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO B. Europ. J. Pharm. 184:119–126.
Salo, P. T. and Tatton, W. G. 1992. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31:394–400.
Zeng, Y. C., Bongrani, S., Bronzetti, E., Cadel, S., Ricci, A., Valsecchi, B., and Amenta, F. 1995. Effect of long-term treatment with L-deprenyl on the age-dependent microanatomical changes in the rat hippocampus. Mech. Ageing Develop. 79:169–185.
Stoll, S., Hafner, U., Pohl, O., and Muller, W. E. 1994. Agerelated memory decline and longevity under treatment with selegiline. Life Sci. 55:2155–2163.
Head, E., Hartley, J., Kameka, A. M., Mehta, R., Ivy, G. O., Rhehl, W. W., and Milgram, N. W. 1996. The effects of Ldeprenyl on spatial short term memory in young and aged dogs. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 20:515–530.
Knollema, S., Aukema, W., Hom, H., Korf, J., and Ter Horst, G. J. 1995. L-deprenyl reduces brain damage in rats exposed to transient hypoxia-ischemia. Stroke 26:1883–1887.
Matsui, Y. and Kumagae, Y. 1991. Monoamine oxidase inhibitors prevent striatal neuronal necrosis induced by transient forebrain ischemia. Neurosci. Lett. 126:175–178.
Semkova, I., Wolz, P., Schilling, M., and Krieglstein, J. 1996. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Europ. J. Pharm. 315:19–30.
Fowler, J. S., Volkow, N. D., Logan, J., et al. 1994. Slow recovery of human brain MAO B after L-deprenyl (Selegiline) withdrawal. Synapse 18:86–93.
Wu, R. M., Mohanakumar, K. P., Murphy, D. L., and Chiueh, C. C. 1994. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (Selegiline). Ann. NY Acad. Sci. 738:214–221.
Thiffault, C., Aumont, N., Quirion, R., and Poirier, J. 1995. Effect of MPTP and L-deprenyl on antioxidant enzymes and lipid peroxidation levels in mouse brain. J. Neurochem. 65:2725–2731.
Carrillo, M. C., Kanai, S., Sato, Y., Nokubo, M., Ivy, G. O., and Kitani, K. 1993. The optimal dosage of (-)deprenl for increasing superoxide dismutase activities in several brain regions decreases with age in male fischer 344 rats. Life Sci. 52:1925–1934.
Kitani, K., Miyasaka, K., Kania, S., Carillo, M. C., and Ivy, G. O. 1996. Upregulation of antioxidant enzyme activities by deprenyl. Ann. N.Y. Acad. Sci. 786:391–409.
Tatton, W. G. and Chalmers-Redman, R. M. 1998. Mitochondria in neurodegenerative apoptosis: an opportunity for therapy? [Review] [82 refs]. Ann. Neurol. 44:S134–S141.
Wadia, J. S., Chalmers-Redman, R. M. E., Ju, W. J. H., Carlile, G. W., Phillips, J. L., Fraser, A. D., and Tatton, W. G. 1998. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurochem. 18:932–945.
Lai, C.-T. and Yu, P. H. 1997. R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells. Toxicol. App. Pharmacol. 142:186–191.
The Parkinson Study Group. 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New England J. Med. 328:176–183.
Myllyla, V. V., Sotaniemi, K. A., Hakulinen, P., Maki-Ikola, O., and Heinonen, E. H. 1998. Selegiline as the primary treatment of Parkinson's disease—a long-term double-blind study. Acta Neurol. Scand. 95:211–218.
Olanow, C. W., Hauser, R. A., Gauger, L., Malapira, T., Koller, W., Hubble, J., Bushenbark, K., Lilienfeld, D., and Esterlitz, J. 1998. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38:771–777.
Wrona, M. Z., Yang, Z., Zhang, F., and Dryhurst, G. 1997. Potential new insights into the molecular mechanisms of methamphetamine-induced neurodegeneration. NIDA Res. Monograph 173:146–174.
Romero-Ramos, M., Rodriguez-Gomez, J. A., Venero, J. L., Cano, J., and Machado, A. 1997. Chronic inhibition of the highaffinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Free Radical Biol. Med. 23:1–7.
Fang, J. and Yu, P. H. 1994. Effect of L-deprenyl, its structural analogue and some monoamine oxidase inhibitors on dopamine uptake. Neuropharmacology 33:763–768.
Heikkila, R. E., Cabbat, F. S., Manzino, L., and Duvoisin, R. C. 1981. Pontentiation by deprenil of L-Dopa induced circling in nigral-lesioned rats. Pharmacol. Biochem. Behav. 15:75–78.
Knoll, J. 1992. The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: A personal view. Pharmacol. & Toxicol. 70:317–321.
Dourish, C. T. 1982. A pharmacological analysis of the hyperactivity syndrome induced by beta-phenylethylamine in the mouse. Br. J. Pharmacol. 77:129–139.
Sato, S., Tamura, A., Kitagawia, S., and Koshiro, A. 1997. A kinetic analysis of the effects of beta-phenylethylamine on the concentrations of dopamine and its metabolites in the rat striatum. Journal of Pharmaceutical Sciences 86:487–496.
Shannon, H. E. and DeGregorio, C. M. 1982. Self-administration of the endogenous trace animes beta-phenylethylamine, N-methyl phenylethylamine and phenylethanolamine in dogs. J. Pharmacol. Exper. Ther. 222:52–60.
Yu, P. H., Davis, B. A., Durden, D. A., Barber, A., Terleckyj, I., Nicklas, W. G., and Boulton, A. A. 1994. Neurochemical and neuroprotective effects of some aliphatic propargylamines:new selective nonamphetamine-like monamine oxidase inhibitors. J. Neurochem. 62:697–704.
Knoll, J. 1990. Nigrostriatal dopaminergic activity, (-) deprenyl treatment and longevity. Advan. Neurol. 53:425–429.
Kopin, I. J. 1994. Neurotransmitters and disorders of the basal ganglia. Pages 899–918, in Siegel, G. J., Agranoff, B. W., Albers, R. W., and Molinoff, P. B. (eds.), Basic Neurochemistry Vol.5, Raven Press, New York.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grasing, K., Azevedo, R., Karuppan, S. et al. Biphasic Effects of Selegiline on Striatal Dopamine: Lack of Effect on Methamphetamine-Induced Dopamine Depletion. Neurochem Res 26, 65–74 (2001). https://doi.org/10.1023/A:1007632700126
Issue Date:
DOI: https://doi.org/10.1023/A:1007632700126